25.05.2017 • NewsElaine BurridgeNovartisdiseases

Novartis in Pakistan Drug Program

(c) Novartis
(c) Novartis

Novartis has signed a Memorandum of Understanding (MoU) with Pakistan’s Ministry of National Health Services, Regulations and Coordination to increase access to treatment for poor people suffering from chronic diseases.

Under the MoU, Novartis and the ministry will collaborate to deliver a program called Novartis Access. This program will ensure access to high-quality medicines in the public sector, primarily targeting four key non-communicable diseases: cardiovascular diseases; diabetes; respiratory illnesses; and breast cancer. These illnesses are said to be responsible for nearly one-fifth of deaths in people aged between 30 and 70 in Pakistan every year.

In a pilot phase, Novartis Access drugs will be made available free-of-charge through selected empanelled hospitals in Islamabad under the Prime Minister’s National Health Program. Work has already started to extend the initiative to all districts in the National Health Program.

National Health Services Regulations and Coordination minister, Saira Afzal Tarar, said Pakistan is grievously affected by the growth of non-communicable diseases and having access to high-quality treatment at low cost is a critical part of its work to lessen the impact of chronic illnesses in the country.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.